London-Based Hypervision Surgical Raises £17M In Series A Funding

The round included investors such as Angelini Ventures, HERAN Partners, Redalpine, LifeX Ventures, ZEISS Ventures, and SINC Fund, managed by SAGES Ingenuity.

The company will use the funding to expand its operations and accelerate research and development.

Led by CEO Michael Ebner, Hypervision Surgical is a medtech spin-out from King’s College London. Its platform combines proprietary spectral sensing with AI-driven analytics to provide real-time, quantitative insights into tissue during surgery.

Read Also - Gifting Platform Udora Raises $10 Million To Expand In Europe After Rebranding From Flowwow

The company aims to integrate its technology into laparoscopic, robotic, microscopic, and endoscopic surgical systems to enhance surgical precision and decision-making.

This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision. By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery giving surgeons real-time insights into tissue that were previously impossible to access. Michael Ebner, CEO and co-founder of Hypervision Surgical.

About Hypervision Surgical

Hypervision Surgical founded in 2021 from King’s College London builds imaging technology to help surgeons see tissues more clearly during operations. Using safe light and AI it provides real time insights helping doctors perform safer faster surgeries and improve patient outcomes.